GlassScriptPhysician profile
Lisa R Davidson
NPI 1184603193
$113,077.26
in general payments reported to CMS, 2019-2025
50 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $19K · 2021: $21K · 2022: $17K · 2023: $4,754 · 2024: $9,598 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $1,979 · Food and Beverage: $1,507 · Education: $28.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,487.50 |
| Travel and Lodging | $1,979.24 |
| Food and Beverage | $1,506.55 |
| Education | $28.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,799.78 | 2019-2025 | Botox, Qulipta |
| Teva Pharmaceuticals USA, INC. | $35,617.28 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $32,738.92 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $181.68 | 2023-2025 | |
| Ucb, INC. | $132.66 | 2020-2025 | Nayzilam, Briviact |
| Tanabe Pharma America, INC. | $110.63 | 2019-2023 | |
| Biogen, INC. | $101.81 | 2019-2022 | |
| Lundbeck LLC | $97.35 | 2020-2025 | Rexulti, Vyepti |
| Amgen INC. | $94.74 | 2021-2025 | Aimovig, Uplizna, Repatha |
| Novartis Pharmaceuticals Corporation | $86.28 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $60.01 | 2020-2024 | |
| Acorda Therapeutics, INC | $56.38 | 2019-2023 | Inbrija |
| Janssen Pharmaceuticals, INC | $54.80 | 2021-2022 | |
| Corium, LLC | $53.30 | 2022-2023 | Adlarity |
| Eisai INC. | $49.77 | 2020-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.